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J. J. Espinós, and the Spanish Working Group for Hirsutism
Department of Gynaecology (J.C., J.J.E.), Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain; Department of
Gynaecology (E.L.), Hospital Virgen de la Arrixaca, 30120 Murcia, Spain; Department of Gynaecology (A.M.), Hospital
Clı́nico Universitario de Valencia, 46010 Valencia, Spain; Department of Endocrinology (J.A.), Clı́nica Puerta de Hierro,
28035 Madrid, Spain; Department of Gynaecology (A.F.), Hospital Clı́nic i Provincial de Barcelona, 08036 Barcelona,
Spain; Department of Endocrinology (O.V.), Hospital Juan Canalejo, 15006 La Coruña, Spain; Department of Gynaecology
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Objective: Our objective was to test the efficacy and tolerability of
three doses of flutamide (125, 250, and 375 mg) combined with a
triphasic oral contraceptive (ethynylestradiol/levonorgestrel) during
12 months to treat moderate to severe hirsutism in patients with
polycystic ovary syndrome or idiopathic hirsutism.
Design: We conducted a randomized, double-blind, placebo-con-
trolled, parallel clinical trial.
Patients: A total of 131 premenopausal women, suffering from mod-
erate to severe hirsutism, were randomized to placebo or 125, 250, or
375 mg flutamide daily associated with a triphasic oral contraceptive
pill. Hirsutism (Ferriman-Gallwey), acne and seborrhea (Cremon-
cini), and hormone serum levels were monitored at baseline and at 3
(except hormone serum levels), 6, and 12 months. Side effects and
biochemical, hematological, and hepatic parameters were assessed.
Methods: We used three-way ANOVA (subject, dose, and visit) with
Scheffé adjustment for multiple comparisons or nonparametrical
Friedman test and least-squares mean (paired data) and Kruskall-
Wallis test for unpaired data analyses. We used 2 or Fisher’s test for
categorical data.
Results: A total of 119 patients were included in the intention-to-
treat analysis. All flutamide doses induced a significant decrease in
hirsutism, acne, and seborrhea scores after 12 months compared with
placebo without differences among dose levels. Similar related side
effects were observed with placebo and 125 mg flutamide (12.5%), and
slightly higher with 250 mg (17.3%) and 375 mg (21.2%). No statis-
tically significant differences were observed either among doses or
compared with placebo.
Conclusions: Flutamide at 125 mg daily during 12 months was the
minimum effective dose to diminish hirsutism in patients with poly-
cystic ovary syndrome or with idiopathic hirsutism. (J Clin Endo-
crinol Metab 92: 3446–3452, 2007)
HIRSUTISM IS A COMMON disorder affecting 5–8% ofthe whole female population of fertile age (1, 2) and
is defined as the presence of terminal (coarse) hairs in females
in a male-like pattern (3). Hirsutism is a sign of increased
androgen action on hair follicles, from increased bioavailable
circulating androgen levels (either endogenous or exoge-
nous) or from an increased sensitivity of the hair follicle unit
to normal circulating androgen levels (4).
Etiology of the hirsutism can be familial or idiopathic, or it
can be caused by excess androgen secretion by the ovary [e.g.
polycystic ovary syndrome (PCOS) or adrenal glands (e.g. con-
genital adrenal hyperplasia and Cushing’s syndrome) or an
exogenous pharmacological source of androgens (5).
Treatment options can be classified in those for local man-
ifestations (physical methods of hair removal) and those for
the underlying causes. The latter is aimed at blocking the
androgen action at hair follicles or at suppressing the an-
drogen production (5, 6).
The available evidence suggests that cyclical oral contra-
ceptives, spironolactone, and cyproterone acetate are equally
effective, producing subjective and objective improvement in
50–60% of patients at 6 months. Side effects are not uncom-
mon, and many patients discontinue treatment. Moreover,
the administration of oral contraceptives can change the met-
abolic and lipid evolution depending on the dose of estrogen,
type of progestin, and formulation of the preparation (7).
The most commonly used antiandrogens are spironolac-
tone and flutamide. Flutamide, a nonsteroidal drug usually
prescribed for prostatic cancer, is a pure peripheral androgen
antagonist with no progestogenic or antigonadotropic action
and thus does not cause menstrual irregularity (8). The clin-
ical evidence shows flutamide as an effective drug for
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women with idiopathic hirsutism or with a PCOS (9–13);
however, liver toxicity might be a rare but potentially severe
side effect of flutamide (14).
Until now, there is not much evidence to assess the clinical
efficacy and tolerability of flutamide in double-blind, long-
term, and placebo-controlled designs. To address this issue,
131 hirsute women were included in a 12-month course of
double blind, placebo-controlled, randomized treatment
with 125, 250, and 375 mg daily flutamide.
Subjects and Methods
Subjects
A total of 131 women of ages between 18 and 40 yr, who gave their
written consent and had moderate to severe (a score of greater than 15
in the modified Ferriman-Gallwey scale) hirsutism of either idiopathic
or PCOS etiology were included in the study by the 14 recruiting centers
in Spain (safety population). Participation of patients in whom oral
hormonal contraception was contraindicated was not considered. Pa-
tients who had received a diagnosis of iatrogenic hirsutism, ovarian or
adrenal neoplasia, prolactinoma, Cushing’s syndrome, congenital ad-
renal hyperplasia, diabetes mellitus, or thromboembolic disease were
also excluded. Patients who had received treatment with oral hormonal
contraceptives or systemic treatment of their hirsutism over the last 3
months or those who had started a cosmetic treatment for fewer than
30 d before inclusion were also excluded. Once patients had initiated the
study, they were able to start cosmetic treatments based on hair shaving
or bleaching, except during the 30 d before the visit for evaluation of their
degree of hirsutism.
From the 131 patients included, 12 patients did not satisfy the inclu-
sion criteria, and so, even though they were considered in the safety
evaluation, they were excluded from the efficacy evaluation. A total of
119 patients were considered for the intention-to-treat analysis. Of these,
the 77 women who completed the study with no major deviations
formed the Per-Protocol population.
Study design
Patients were randomly assigned to one of the following: 1) placebo
(control group), 2) 125 mg flutamide, 3) 250 mg flutamide, and 4) 375 mg
flutamide, once daily during 12 months in association with a triphasic
oral contraceptive (OC) pill (Triciclor, which is a triphasic treatment of
30, 40, and 30 g ethynylestradiol and 50, 75, and 125 g levonorgestrel).
This study was carried out in double-blind conditions, and so neither the
patient nor the doctor was aware of the composition of the treatment
administered. For this purpose, preparation of the medication was per-
formed in a centralized manner, and labeling, with the exception of the
relevant randomization code, was identical in all four presentations.
The hair growth was estimated by a modification of the Ferriman-
Gallwey scale (15) (Table 1) and the acne and seborrhea by the Crem-
oncini scale (16), in which for acne, a score of 1 indicates isolated pustules
up to 10 in number, 2 indicates more than 10 isolated pustules, 3 indi-
cates clusters of pustules, and 4 indicates confluent pustules; for sebor-
rhea, 1 indicates mild, 2 moderate, and 3 severe. Scores for both scales
TABLE 1. Ferryman-Gallwey modified scale
Site and grade Definition
1. Upper lip
1 A few hairs at outer margin
2 A small moustache at outer margin
3 A moustache extending halfway from outer margin
4 A moustache extending to mid-line
2. Cheek
1 A few scattered hairs
2 Scattered hairs with small concentrations
3 Light complete cover
4 Heavy complete cover
3. Chin
1 A few scattered hairs
2 Scattered hairs with small concentrations
3 Light complete cover
4 Heavy complete cover
4. Chest
1 Circumareolar hairs
2 Circumareolar hairs with mid-line hair in addition
3 Fusion of these areas, with three-quarter cover
4 Complete cover
5. Upper back
1 A few scattered hairs
2 Some more, still scattered
3 Light complete cover
4 Heavy complete cover
6. Lower back
1 A sacral tuft of hair




1 A few midline hairs




1 A few midline hairs
2 A midline streak of hair
3 A midline band of hair
4 An inverted V-shaped growth
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were determined at baseline and at 3, 6, and 12 months. All measures
relative to each patient were made by the same investigator. A standard
hormonal profile, including serum levels of prolactin, estradiol, testos-
terone, dehydroepiandrosterone sulfate (DHEAS), androstenedione,
17-hydroxyprogesterone, SHBG, free androgen index [total testoster-
one (nm)/SHBG (nm)  100], LH, and FSH was assessed every 6 months.
The hormone profile was centralized at one center (Hospital de la Santa
Creu i Sant Pau, Barcelona, Spain).
The safety evaluation comprised continuous adverse event assess-
ment, monthly hematology and hepatic function evaluation, and a phys-
ical examination every 3 months. A biochemistry evaluation was also
included every 6 months.
The study was conducted in accordance with the Declaration of
Helsinki on human experimentation. The study protocol was approved
by every local ethics committee of all the participant centers before the
inclusion of the patients who gave written informed consent before any
study procedure.
Monitoring visits were done at the recruiting centers to perform the
source data verification following good clinical practice. A quality as-
surance plan was implemented for the protocol and all amendments, the
case report form, the medication preparation and packaging, one of the
participating centers (Hospital Juan Canalejo, La Coruña, Spain), the
clinical study report, and the trial master file.
Statistics
The modified Ferriman-Gallwey hirsutism score and the Cremoncini
acne and seborrhea scores were analyzed with a Friedman analysis and
a least-squares mean multiple comparison approach (paired data) and
with a Kruskall-Wallis analysis and Mann-Whitney U tests without any
multiplicity adjustment (unpaired data). The laboratory parameters
were analyzed with a three-way ANOVA (subject, treatment, and visit)
and a Scheffé multiple comparison approach. The Shapiro-Wilk test was
used to assess the normal distribution of the parameters. On the other
hand, the categorical data were analyzed with a 2 or Friedman analysis.
All significance tests were two tailed, and a test P  0.05 was considered
significant. An intent-to-treat approach was used with no replacement
strategy for the missing data, and a sensitivity analysis was used for
confirmation with the per-protocol population. The statistical analysis


















Placebo 125 mg 250 mg 375 mg
 
Day 0 Month 3 Month 6 Month 12
Placebo (n=31) 18.35 (2.44) 14 (5.23) 13.19 (5.5) 13.06 (5.71)
Flutamide 125 mg (n=25) 19.28 (3.36) 13.96 (5.03) 11.28 (5.2) 9.12 (5.14)
Flutamide 250 mg (n=29) 18.72 (2.64) 13.31 (4.57) 11.28 (4.22) 9.52 (4.93)
Flutamide 375 mg (n=34) 18 (2.9) 13.32 (4.61) 11.09 (5.22) 9.29 (5.58)
FIG. 1. Changes from baseline (percent) in the
modified Ferriman-Gallwey (FG) hirsutism score
[mean (SD)]. All treatment groups were associated
with OCs.
TABLE 2. Baseline characteristics of intention-to-treat population
Placebo
Flutamide
125 mg 250 mg 375 mg
n 31 25 29 34
Age (yr) 24.1 (4.85) 24.0 (6.17) 24.6 (5.73) 24.7 (5.58)
Weight (kg) 66.3 (13.63) 66.7 (10.2) 71.0 (17.35) 68.7 (14.91)
Body mass index (kg/m2) 25.4 (5.11) 25.2 (3.28) 26.9 (7.88) 27.3 (6.03)
Waist/hip index 0.78 (0.09) 0.81 (0.07) 0.80 (0.08) 0.79 (0.09)
Modified Ferriman-Gallwey score 18.4 (2.44) 19.3 (3.36) 18.7 (2.64) 18.0 (2.90)
Acne score 0.84 (1.10) 0.88 (0.88) 0.76 (1.15) 0.76 (1.02)
Seborrhea score 0.97 (0.84) 1.00 (1.00) 1.00 (1.04) 0.91 (1.03)
Results are shown as mean (SD).
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Results
The mean age was 24.4 yr (sd 5.5), the mean weight was
68.2 kg (14.34), and the mean weight/hip ratio was 0.80
(0.08).
Hirsutism
With no statistically significant differences at baseline in
the Ferriman-Gallwey hirsutism score (Table 2), flutamide
associated with an OC showed a significant hirsutism pro-
gressive decrease after 12 months of treatment compared
with placebo associated with an OC (P  0.020), with no
differences among doses. At 12 months of treatment, the
patients under placebo reduced their mean baseline hirsut-
ism 28.8%, whereas patients under flutamide reduced it ap-
proximately 50% (52.7, 49.1, and 48.4% with 125, 250, and 375
mg, respectively) (Fig. 1). Although the placebo group
showed a significant decrease at 6 months, it did not show
any additional significant decrease at 12 months.
Acne and seborrhea
Although there were not statistically significant differ-
ences at baseline in the Cremoncini acne and seborrhea
scores (Table 2), flutamide was associated with a significant
improvement at 6 and 12 months for acne (P  0.031 and P 
0.002, respectively) and at 6 months for seborrhea (P  0.012).
No differences were seen among doses. At 12 months, pa-
tients under placebo reduced their mean baseline acne by
46.4%, whereas patients under flutamide reduced it by over
80% (81.8, 86.8, and 88.2%, with 125, 250, and 375 mg, re-
spectively) (Fig. 2). Although the mean seborrhea change
from baseline to 6 months was statistically significant, it lost
significance at 12 months. At 12 months, placebo improved
seborrhea by 56.7% of the baseline seborrhea, whereas flu-
tamide improved it by 88.0% with the 125-mg dose, 72.0%
with the 250-mg dose, and 76.9% with the 375-mg dose
(Fig. 3).
Endocrine features
All of the hormones profiled, except prolactin, showed a
statistically significant change after the first 6 months of
treatment (all hormone levels decreased, and SHBG in-
creased) (Table 3). There were no significant differences
among flutamide doses.
Tolerability
The incidence of adverse events possibly or probably re-
lated to the study drugs was similar between placebo and 125
mg flutamide (12.5%); even though not statistically signifi-
cant, those incidences were higher with 250 mg (17.3%) and
375 mg (21.2%). The adverse events most frequently reported
were upper respiratory tract infection (9.2%), dry skin (9.2%),
headache (7.1%), nausea and vomiting (5.5%), and diarrhea
(3.7%). One serious adverse event in the placebo group (sci-
atica aggravated not related to the study drug) occurred. On
the other hand, there was one significant transaminase in-























Placebo 125 mg 250 mg 375 mg
 
Day 0 Month 3 Month 6 Month 12
Placebo (n=31) 0.84 (1.1) 0.52 (0.81) 0.45 (0.77) 0.45 (0.72)
Flutamide 125 mg (n=25) 0.88 (0.88) 0.36 (0.81) 0.24 (0.72) 0.16 (0.55)
Flutamide 250 mg (n=29) 0.76 (1.15) 0.38 (0.78) 0.21 (0.62) 0.1 (0.56)
Flutamide 375 mg (n=34) 0.76 (1.02) 0.35 (0.77) 0.06 (0.24) 0.09 (0.29)
FIG. 2. Changes from baseline (percent) in the
acne score [mean (SD)]. All treatment groups were
associated with OCs.
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amide, and another one with 375 mg flutamide. The 125-mg
dose did not show any significant transaminase variation. No
significant changes in mean transaminase levels were detected.
From a total of 325 adverse events, 92.3% did not require any
treatment change, 0.6% required a temporal treatment inter-
ruption, and 7.1% concluded in study withdrawals (4.6% with
possible/probable relationship with the study drug). Among
the most frequent adverse events according to systems or or-
gans, the most frequent ones were gastrointestinal disorders
(20.92% of the total adverse events), skin and appendix disor-
ders (19.38%), respiratory tract disorders (18.15%), and vege-
tative nervous system disorders (10,46%). Individually, catarrh
and flu syndrome were significant (9.23%) as well as dry skin
(9.23%), headache (7.08%), nausea (5.54%), vomiting (5.54%),
and diarrhea (3.69%).
Five women withdrew from the study due to clinically
significant laboratory abnormalities (hematology assessed
every month and biochemistry every 6 months): hypergly-
cemia not related to the treatment (placebo), leucopenia (250
mg flutamide) with relationship to study drug not assessed,
and three episodes of transaminases increase possibly or
probably related to the study drug (placebo, 250 mg flut-
amide, and 375 mg flutamide).
The physical examination did not show clinically relevant
changes in the women’s weight, waist to hip ratio, blood
pressure, or heart rate.
Discussion
OCs are usually the first choice for the treatment of hir-
sutism for women who do not wish to become pregnant, but
some maintain that all preparations are comparable in effi-
cacy (17). These agents increase the level of SHBG and there-
fore decrease ovarian androgen biodisponibility while de-
creasing the risk of endometrial hyperplasia often seen in
anovulatory women (9, 17).
For women with idiopathic hirsutism, PCOS, or late-onset
congenital adrenal hyperplasia, childbearing plans should
also be considered. This way, OCs containing less androgenic
progestin, such as norgestimate, gestodene, and desogestrel,
seem to be the best choice, because they increase the SHBG
level and decrease the androgen bioavailability (9, 17). GnRH
analogs should be reserved for use in women who do not
respond to combination hormonal therapy or those who
cannot tolerate OCs.
Spironolactone has been widely used for hirsutism, par-
ticularly in those women in whom estrogens are contrain-
dicated. It is an aldosterone antagonist that has no suppres-
sive effect on androgen levels but blocks androgen action
through its ability to compete with testosterone and dihy-
drotestosterone by binding to the androgen receptor (18).
To diminish the limitation that implies the potential vari-
ability in hirsutism assessment judged by different investi-
gators in this multicenter study, all measurements relative to
each patient were obtained by the same investigator.
Although contraception pills were effective for hirsutism
control as shown by the reduced Ferriman-Gallwey score in
the placebo group, this study provides clear evidence of the
increased efficacy induced by the addition of flutamide to
oral contraception for the treatment of hirsutism either at 125,


























Placebo 125 mg 250 mg 375 mg
Day 0 Month 3 Month 6 Month 12
Placebo (n=31) 0.97 (0.84) 0.58 (0.76) 0.55 (0.81) 0.42 (0.72)
Flutamide 125 mg (n=25) 1 (1) 0.32 (0.56) 0.04 (0.2) 0.12 (0.33)
Flutamide 250 mg (n=29) 1 (1.04) 0.38 (0.68) 0.21 (0.49) 0.28 (0.7)
Flutamide 375 mg (n=34) 0.91 (1.03) 0.44 (0.66) 0.24 (0.5) 0.21 (0.54)
FIG. 3. Changes from baseline (percent) in the
seborrhea score [mean (SD)]. All treatment groups
were associated with OCs.
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Flutamide reduced the modified Ferriman-Gallwey score by
52.7% (125 mg), 49.1% (250 mg), and 48.4% (375 mg) after 12
months of daily treatment, whereas the placebo control
group reduced that score by only 28.8%. The improvement
in the flutamide group was maintained during the whole
12-month period, whereas improvement with placebo was
seen only during the first 6 months, being probably due to
the associated OC treatment. No statistically significant dif-
ferences were obtained for the different doses of flutamide.
We have found similar reductions in the Ferriman-Gall-
wey hirsutism scores in other previous studies with flut-
amide at higher different doses (ranging from 250–500 mg)
(19–23). Moreover, our score reduction is even more than the
highest reduction obtained by Muderris and colleagues with
the 125-mg daily dose (24), with the 250-mg daily dose (23,
25), and with the 62.5-mg daily dose (26). For all those stud-
ies, however, we have found no differences among the flu-
tamide doses tested.
In addition to the hirsutism score, we found a statistically
significant reduction of the Cremoncini acne and seborrhea
scores after 12 months of treatment, with a higher decrease
up to 6 months compared with 12 months with the flutamide
doses, as was found by other authors with the 250-mg dose
(10, 11).
Our findings are in agreement with those published by
others reporting a reduction in plasma levels of LH, FSH,
estradiol, testosterone, androstenedione, and DHEAS (8, 21–
23, 27, 28). We have also identified a decrease in 17OH-
progesterone and the free androgen index. A significant part
of these hormonal changes is the consequence of the blockade
on the hypothalamic-pituitary-gonadal axis exerted by OCs.
DHEAS, a metabolite predominantly adrenal in origin, also
decreases with the three doses of flutamide. This can be
because flutamide not only causes blockade of androgen
receptors but also acts on the adrenals to reduce adrenal
androgen synthesis (29, 30). On the other hand, SHBG serum
levels were increased with all the tested doses, thus decreas-
ing androgen bioavailability.
The tolerability of flutamide was good, with no differences
in the incidences of adverse events possibly or probably
related to the study drugs along the study period. Unlike
other published results (21, 22), skin dryness probably re-
lated to the flutamide action mechanism inhibiting the se-
bum production was found in a lower incidence.
On the other hand, we did not find a significant liver
toxicity (31, 32), with no significant transaminase variations
in the 125-mg flutamide group, one significant transaminase
increase in the placebo group, another with 250 mg flut-
amide, and another with 375 mg flutamide. However, be-
cause rare serious or even fatal hepatic side effects have been
previously been reported with flutamide, adequate safety
studies should be performed before advising for systematic
coadministration of this product in the treatment of severe
hirsutism.
In conclusion, this double-blind, placebo-controlled study
shows that flutamide, even at the 125-mg dose, associated
with OCs, is a very satisfactory therapeutic regimen in the
treatment of hirsutism and better than OCs used alone. This
association shows a very good safety profile, as evaluated
only on changes in transaminase levels, and decreases the
TABLE 3. Hormonal profile, at baseline and after 6 and 12 months
Placebo
Flutamide
125 mg 250 mg 375 mg
n 31 25 29 34
Testosterone (nmol/liter)
Baseline 2.15 (0.91) 2.21 (1.13) 2.46 (1.17) 2.28 (0.71)
Month 6 1.63 (0.61) 1.63 (0.68) 1.84 (0.96) 1.91 (0.75)
Month 12 1.64 (0.69) 2.05 (1.05) 1.87 (0.71) 2.10 (0.79)
SHBG (nmol/liter)
Baseline 57.2 (41.00) 49.2 (52.21) 37.8 (23.69) 45.7 (47.4)
Month 6 93.6 (41.59) 183.6 (90.39) 161.3 (95.60) 165.8 (96.9)
Month 12 94.8 (52.22) 158.3 (70.39) 142.1 (103.27) 175.1 (103.23)
Free androgen index
Baseline 5.06 (2.63) 7.58 (7.54) 8.09 (5.32) 7.12 (4.17)
Month 6 2.33 (2.09) 2.73 (7.39) 2.04 (2.42) 2.50 (4.20)
Month 12 2.86 (3.91) 2.96 (7.33) 2.68 (3.27) 2.40 (3.92)
Estradiol (nmol/liter)
Baseline 0.14 (0.12) 0.13 (0.08) 0.16 (0.16) 0.13 (0.11)
Month 6 0.07 (0.04) 0.14 (0.26) 0.10 (0.17) 0.06 (0.06)
Month 12 0.07 (0.04) 0.07 (0.05) 0.07 (0.05) 0.13 (0.21)
DHEAS (nmol/liter)
Baseline 7.62 (2.51) 7.07 (2.98) 7.85 (3.32) 6.91 (2.46)
Month 6 7.20 (2.63) 4.48 (2.08) 4.42 (1.75) 3.91 (1.94)
Month 12 6.55 (2.58) 4.48 (2.14) 4.32 (1.90) 3.81 (2.00)
Androstenedione (nmol/liter)
Baseline 9.69 (3.83) 12,90 (6.98) 11.41 (3.79) 11.06 (4.12)
Month 6 7.56 (3.45) 8.33 (3.38) 7.66 (4.13) 8.60 (3.89)
Month 12 7.70 (3.38) 9.20 (5.31) 7.74 (3.55) 9.16 (4.37)
17OH-progesterone (nmol/liter)
Baseline 2.85 (2.09) 2.93 (2.04) 2.69 (1.87) 3.01 (1.86)
Month 6 2.08 (1.75) 2.04 (1.88) 1.68 (0.98) 1.85 (1.08)
Month 12 1.90 (1.72) 2.06 (1.91) 1.69 (0.98) 1.83 (0.82)
Results are shown as mean (SD).
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risk of becoming pregnant during the antiandrogen treat-
ment. Because the flutamide liver toxicity is dose dependent,
the high risk/benefit ratio could be reduced by using the
lower doses of this drug. Additional studies comparing
the 62.5- and 125-mg flutamide daily doses could define the
risk-benefit and cost effectiveness of these lower doses in the
treatment of hirsutism to be used in place of high-dose flu-
tamide, 250–750 mg/d.
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